172 related articles for article (PubMed ID: 21471822)
1. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.
Yi JH; Yi SY; Lee HR; Lee SI; Lim DH; Kim JH; Park KW; Lee J
Melanoma Res; 2011 Jun; 21(3):223-7. PubMed ID: 21471822
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
3. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
Chang W; Lee SJ; Park S; Choi MK; Hong JY; Kim YS; Maeng CH; Jung HA; Kim S; Lee J
Melanoma Res; 2013 Apr; 23(2):147-51. PubMed ID: 23411477
[TBL] [Abstract][Full Text] [Related]
4. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
6. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
7. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
8. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
9. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
Cocconi G; Bella M; Calabresi F; Tonato M; Canaletti R; Boni C; Buzzi F; Ceci G; Corgna E; Costa P
N Engl J Med; 1992 Aug; 327(8):516-23. PubMed ID: 1635566
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
[TBL] [Abstract][Full Text] [Related]
13. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Teimouri F; Nikfar S; Abdollahi M
Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
16. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Hauschild A; Grob JJ; Demidov LV; Jouary T; Gutzmer R; Millward M; Rutkowski P; Blank CU; Miller WH; Kaempgen E; Martín-Algarra S; Karaszewska B; Mauch C; Chiarion-Sileni V; Martin AM; Swann S; Haney P; Mirakhur B; Guckert ME; Goodman V; Chapman PB
Lancet; 2012 Jul; 380(9839):358-65. PubMed ID: 22735384
[TBL] [Abstract][Full Text] [Related]
18. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
Bouchereau S; Chaplain L; Fort M; Beauchet A; Sidibé T; Chapalain M; Gonzalez-Lara L; Longvert C; Blom A; Saiag P; Funck-Brentano E
Br J Cancer; 2021 Sep; 125(7):948-954. PubMed ID: 34262147
[TBL] [Abstract][Full Text] [Related]
19. New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Hwu WJ
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):25-8. PubMed ID: 11204670
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]